Celanese account plan
Chemical material solutions production
At a glance
Celanese is a global chemical and specialty materials company with FY2025 net sales of $9,544 million and 11,434 employees.
Celanese, headquartered in Irving, Texas and listed on the NYSE as CE, produces engineered polymers and acetyl products used in automotive, medical, electronics, construction, paints and coatings, packaging and many other industries. It runs 51 global production facilities plus 20 strategic affiliate production facilities, mainly in North America, Europe and Asia. FY2025 net sales were $9,544 million, down 7%, with a net loss attributable to Celanese of $(1,165) million driven by $1,513 million of asset impairment losses. It had 11,434 employees at December 31, 2025, and total debt of $12.6 billion makes deleveraging its overriding priority.
Business units
Engineered Materials
$5,390 million FY2025 net sales, about 56% of group net salesHigh performance engineered polymers such as POM, nylon compounds, LCP and UHMW-PE sold to OEMs and suppliers in automotive, medical, electronics and industrial markets. Medical and electronics are less than one-fifth of its sales but nearly 30% of its earnings; Q3 2026 adjusted EBIT was $209 million. Led by Todd Elliott, SVP Engineered Materials.
Acetyl Chain
$4,232 million FY2025 net sales, about 44% of group net salesAn integrated chain from acetic acid and VAM to emulsion polymers, redispersible powders, EVA and acetate tow. Nearly 75% of its sales are in the Western Hemisphere; Q3 2026 net sales rose 13.9% to $1,209 million. Led by Mark C. Murray, SVP Acetyls.
Strategic priorities
- Deleveraging
- Total debt cut to $11,545 million at September 30, 2026 from $12,598 million at end-2025; net debt to operating EBITDA expected at about 4.7x at end-2026, with buybacks paused and the dividend about 95% below pre-2025 levels.
- Free cash flow
- 2026 free cash flow guidance raised to $750-800 million, with more than $1.5 billion expected across 2025 and 2026; the CFO is confident in a similar range for 2027.
- Divestitures
- Target of about $1 billion of proceeds through end-2027; the Micromax sale and the Nutrinova stake sale bring cumulative proceeds to nearly two-thirds of it.
- Grow & Fortify in Engineered Materials
- About 30 priority subsegments in AI infrastructure, medical devices and vehicle electrification; AI infrastructure is sized at a serviceable addressable market of over $1.0 billion by 2030.
- Cost and footprint
- Ulsan, Lanaken and nylon 6,6 actions deliver over $50 million of annualized fixed-cost savings, and a $150 million gross productivity target aims to offset 2027 inflation.
Latest results
In Q3 2026 net sales rose 6% to $2,556 million, with price up 10% and volume down 4%. Operating profit was $198 million against a $(1,275) million loss a year earlier, when Engineered Materials booked impairments, and diluted EPS was $0.67; adjusted EPS was $1.65, up 23%. Engineered Materials net sales slipped 1.2% to $1,368 million after the Micromax sale, while Acetyl Chain net sales rose 13.9% on regional supply dislocation. Nine-month net sales were $7,645 million, up 4%. Celanese raised its 2026 outlook to adjusted EPS of about $6.00-6.25 and free cash flow of $750-800 million.
Investments and deals
- Capital expenditure
- Capex of $343 million in 2025 and about $300-350 million guided for 2026, focused on maintenance and productivity.
- Nanjing LCP plant and compounding
- The Nanjing LCP facility is on schedule for completion by the end of 2026 with production in 2027; specialty compounding in Europe and medical-grade compounding in Asia are to be commercialized in H1 2027.
- Frankfurt VAE expansion
- The Frankfurt VAE emulsion expansion was completed and started production in Q3 2026.
- Micromax and Nutrinova sales
- Micromax sold to Element Solutions for $492 million (closed February 2, 2026); agreement of August 31, 2026 to sell 19% of Nutrinova to Mitsui for about $152 million.
- Site closures
- Lanaken (Belgium) acetate tow manufacturing ceased in Q3 2026, worth about $20 to $25 million of annualized savings; closures at Sakra (Singapore) and Ulsan (South Korea).
Challenges and risks
- High leverage and covenants
- Total debt of $12.6 billion at end-2025; step-downs of the leverage covenant on the $1.75 billion U.S. revolving facility from Q1 2026 were flagged as a compliance risk without mitigation.
- Weak end markets
- Demand stayed weak in automotive, paints, coatings and construction; auto volumes are down in 2026, mainly on lower China builds.
- Raw material and energy costs
- Higher ethylene and methanol costs, European energy costs and Rhine River logistics disruptions weighed on results in 2026.
- Asian competition and overcapacity
- New capacity added in Asia brings more competition on standard grades, and acetate tow market conditions have been challenging.
- Impairments
- $1,513 million of asset impairment losses in FY2025; further goodwill and intangible impairments are listed as possible.
What leadership says
“Together, medical and electronics represent less than one-fifth of EM sales, yet contribute nearly 30 percent to earnings.”
“The specialty polymer demand for an AI server is approximately three times greater than for a conventional server”
“we are seeing kind of a generational spike in demand coming from kind of the global data center build out around AI”
“We are confident in this 7 to 800 range for next year.”
Where a supplier can help
- Manufacturing productivity and AI
- Tied to the $150 million gross productivity target: AI-based tools for raw material efficiency, energy and maintenance that the CEO calls next generation productivity.
- Energy and raw material cost management
- Tied to the raw material and energy cost challenge: procurement analytics, energy efficiency and supply chain agility.
- Electronics and medical application development
- Tied to the Grow & Fortify priority: partners and tooling that help commercialize polymers for AI servers, connectors and drug delivery devices.
- Divestiture and transaction support
- Tied to the $1 billion divestiture target: advisory and separation services for joint-venture transactions.
- Working capital and cash flow
- Tied to the free cash flow and deleveraging priorities: inventory and receivables optimization, as inventories remain elevated.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Celanese?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Celanese Corporation Annual Report on Form 10-K for fiscal year 2025
- Celanese is a global chemical and specialty materials company (NYSE: CE, HQ Irving, Texas) operating through two segments, Engineered Materials and the Acetyl Chain, with 51 global production facilities plus 20 strategic affiliate production facilities and 11,434 employees at December 31, 2025.
- FY2025 net sales were $9,544 million, down $724 million (7%) from $10,268 million, on lower volume (-4%) and lower price (-4%), partly offset by currency (+1%); operating loss was $(786) million and net loss attributable to Celanese $(1,165) million, driven by $1,513 million of asset impairment losses.
- Engineered Materials net sales $5,390 million (-3.7%), operating loss $(958) million after impairments; Acetyl Chain net sales $4,232 million (-11.1%), operating profit $539 million (down 43.0% from $946 million).
- Deleveraging is the overriding priority: total debt $12.6 billion at year-end, quarterly dividend cut by about 95% from Q1 2025 ($0.03 per share), share buybacks paused, capex held at $343 million in 2025 with $300-350 million expected for 2026.
- Portfolio actions: Micromax business sold to Element Solutions for $492 million (closed February 2, 2026); Lanaken, Belgium (acetate tow, Acetyl Chain) closure announced October 2025 with $140 million of further exit costs through 2027; earlier closures at Uentrop (Germany) and Mechelen (Belgium).
- Growth investments continue at low capital: Nanjing compounding expansion started production in Q4 2025, a new LCP plant in Nanjing is due in H2 2026, and a VAE emulsion expansion in Frankfurt is due to start in H1 2026.
- Key risk flagged: scheduled step-downs of the leverage covenant on the $1.75 billion U.S. revolving facility from Q1 2026 mean Celanese "may be unable to comply" without mitigation (amendment, waiver, divestitures, cost cuts); demand stayed weak in automotive, paints, coatings and construction.
- Celanese Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 net sales $2,556 million, up 6% from $2,419 million (price +10%, volume -4%); nine-month net sales $7,645 million, up 4%.
- Q3 operating profit $198 million vs a $(1,275) million loss a year earlier, when Engineered Materials booked goodwill and trade-name impairments; net earnings attributable to Celanese $74 million (diluted EPS $0.67).
- Engineered Materials: Q3 net sales $1,368 million (-1.2%, volume -6% after the Micromax sale, price +5%), operating profit $161 million.
- Acetyl Chain: Q3 net sales $1,209 million (+13.9%, price +14% on "regional supply dislocation" and higher raw material costs), operating profit $141 million (+4.4%).
- Total debt cut to $11,545 million from $12,598 million at end-2025; cash $1,362 million; Micromax sold for $493 million (February 2026).
- Agreement (August 31, 2026) to sell 19% of Nutrinova to Mitsui for about $152 million, keeping 11%, closing expected in Q4 2026; Lanaken (Belgium) manufacturing fully ceased in Q3 2026.
- Footprint actions also include closures at Sakra (Singapore) and Ulsan (South Korea) and optimization of North American nylon 6,6 polymerization; the Frankfurt VAE expansion started production in Q3 2026.
- Celanese third quarter 2026 earnings prepared comments (CEO and CFO)
- Q3 2026 adjusted EPS $1.65, up 23% year on year, and free cash flow of $461 million; Celanese expects more than $1.5 billion of free cash flow across 2025 and 2026.
- Engineered Materials: adjusted EBIT $209 million (15% margin), operating EBITDA $311 million; medical net sales +16% and electronics +30% year on year; medical and electronics are less than one-fifth of EM sales but nearly 30% of its earnings.
- EM strategy targets about 30 priority subsegments (AI infrastructure, medical devices, vehicle electrification); new partnership with Vigor on plastic joints for humanoid robotics; LCP plant, European specialty compounding and Asian medical-grade compounding to be commercialized in H1 2027.
- Acetyl Chain: adjusted EBIT $236 million (20% margin), net sales +14%; nearly 75% of AC sales are in the Western Hemisphere and turning acid into emulsions or RDP raises margin contribution "approximately 6 to 8 times".
- Lanaken acetate tow closure completed, worth about $20-25 million of annualized savings; Nutrinova 19% stake sale to Mitsui for about $152 million is nearly two-thirds of the way to the $1 billion divestiture target through 2027.
- 2026 guidance raised: free cash flow $750-800 million, adjusted EPS about $6.00-6.25, net debt-to-operating EBITDA about 4.7x at year-end (4.9x at Q3).
- Investor event in December at the Florence, Kentucky technical center to detail strategy and growth pathways.
- Celanese Q3 2026 earnings call transcript (Q&A with CEO Scott Richardson and CFO Chuck Kyrish)
- The call was Q&A only; CEO Scott Richardson and CFO Chuck Kyrish took questions from about a dozen analysts.
- 2027 framing: Kyrish is "confident in this 7 to 800 range" of free cash flow for 2027, with restructuring cash outlay falling to about $30-40 million and no need to raise capex.
- Cost tailwinds into 2027: about $30-40 million more savings from actions already taken (after $70 million in 2026), about $20 million from normalizing functional costs, about $40 million of net interest savings, and a $150 million gross productivity target to offset inflation.
- Richardson sees "a generational spike in demand coming from kind of the global data center build out around AI" and expects medical and electronics momentum to continue into 2027.
- Auto volumes are down in 2026, mainly on lower China builds, but Richardson likes "the quality of our auto business today better than we did a couple of years ago"; nylon margins have "significantly improved" since Celanese started buying rather than making more polymer.
- Divestitures: the remaining roughly $340 million to the $1 billion target should come from a series of joint-venture transactions about the size of Nutrinova, and divestitures may continue beyond the target.
- Acetyl Chain: methanol is 40-50% integrated by design; Q4 includes an unplanned outage at a key Chinese supplier, Rhine River and European energy costs, and a usual Q3-to-Q4 seasonal decline of about $25 million.
- Celanese second quarter 2026 earnings prepared comments (CEO and CFO)
- Q2 2026 adjusted EPS $2.45, "our highest in nearly three years", with operating EBITDA up more than 20% year on year despite soft demand.
- Engineered Materials: adjusted EBIT $234 million (16% margin) and the highest quarterly total variable margin in its history; medical net sales +19%, electronics +11%; ex-Micromax net sales +6% (price +5%).
- EM growth markets sized by Celanese: AI infrastructure (serviceable addressable market over $1.0 billion by 2030, growing about 20% a year; an AI server needs about three times the specialty polymer of a conventional one), electric drive units (over $1.0 billion by 2030) and drug delivery and patient monitoring (approaching about $500 million by 2030).
- Acetyl Chain: adjusted EBIT $321 million (24% margin), the best since Q2 2023; China supply disruptions proved temporary, and the Western Hemisphere is "the primary driver of earnings power".
- Footprint: Ulsan compounding closed and nylon 6,6 optimization completed early; with Lanaken, these give over $50 million of annualized fixed-cost savings.
- CFO: Q2 free cash flow $140 million; bonds of $508 million and $400 million repaid with cash, leaving no other 2026 maturities; 2026 free cash flow target $700-800 million; full-year adjusted EPS about $6.00.
Questions about Celanese
What does Celanese do?
Celanese makes engineered polymers (Engineered Materials) and acetyl products (Acetyl Chain) used in automotive, medical, electronics, construction, coatings and other industries.
What is Celanese's revenue?
FY2025 net sales were $9,544 million, down 7%. Q3 2026 net sales were $2,556 million, up 6%.
How many employees does Celanese have?
11,434 employees at December 31, 2025.
What is Celanese's strategy?
Deleveraging through free cash flow, cost cuts and about $1 billion of divestitures by end-2027, while growing Engineered Materials in AI infrastructure, medical devices and vehicle electrification.
Who leads Celanese?
Scott A. Richardson has been President and CEO since January 1, 2025; Chuck B. Kyrish is SVP and CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)